Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2016 - 2023)

Historic Depreciation & Amortization (CF) for Spyre Therapeutics (SYRE) over the last 9 years, with Q2 2023 value amounting to $360000.0.

  • Spyre Therapeutics' Depreciation & Amortization (CF) fell 476.19% to $360000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $360000.0, marking a year-over-year decrease of 7674.42%. This contributed to the annual value of $744000.0 for FY2023, which is 5252.07% down from last year.
  • As of Q2 2023, Spyre Therapeutics' Depreciation & Amortization (CF) stood at $360000.0, which was down 476.19% from $384000.0 recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Depreciation & Amortization (CF) registered a high of $412000.0 during Q3 2021, and its lowest value of $100000.0 during Q1 2019.
  • Its 5-year average for Depreciation & Amortization (CF) is $294500.0, with a median of $364500.0 in 2020.
  • In the last 5 years, Spyre Therapeutics' Depreciation & Amortization (CF) skyrocketed by 24811.32% in 2020 and then tumbled by 632.6% in 2022.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Depreciation & Amortization (CF) stood at $106000.0 in 2019, then soared by 248.11% to $369000.0 in 2020, then grew by 11.38% to $411000.0 in 2021, then fell by 6.33% to $385000.0 in 2022, then decreased by 6.49% to $360000.0 in 2023.
  • Its Depreciation & Amortization (CF) stands at $360000.0 for Q2 2023, versus $384000.0 for Q1 2023 and $385000.0 for Q4 2022.